文献速递艾滋病与性传播感染

妊娠期启动抗逆转录病毒治疗女性中依从性、病毒载量升高与耐药突变的巢式病例对照研究

Antiretroviral Adherence, Elevated Viral Load, and Drug Resistance Mutations in Human Immunodeficiency Virus-infected Women Initiating Treatment in Pregnancy: A Nested Case-control Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

在南非开普敦妊娠期启动抗逆转录病毒治疗(ART)的女性队列中,采用巢式病例对照设计比较初始抑制后病毒载量(VL)升高者(80例)与持续抑制者(87例)。估计VL升高<10%可归因于治疗前DRM,>90%归因于ART不依从。

要点

  • 妊娠期启动ART后12个月内VL升高主要与不依从相关,而非治疗前耐药突变。
  • VL升高时仅19%病例血浆中检测到抗逆转录病毒药物,提示服药缺失。
  • 治疗前DRM均为非核苷类逆转录酶抑制剂突变,占比低(病例10% vs 对照5%)。

核心结论

  • 在该队列中,妊娠期启动ART后12个月内发生的VL升高,耐药突变仅占很小比例,不依从驱动了大多数VL升高事件。

研究设计与样本

  • 在南非开普敦妊娠期启动ART的女性队列中开展巢式病例对照研究,比较初始抑制后VL升高者(病例,n=80)与持续抑制者(对照,n=87),按发病密度匹配。

主要发现

  • VL升高时,19%的病例血浆中检测到抗逆转录病毒药物,而匹配时间点持续抑制的对照组中87%检测到药物(aOR 131.43,95%CI 32.8-527.4)。
  • 基于上述发现估计,队列中所有VL升高<10%可能归因于治疗前DRM,>90%归因于ART不依从。

临床怎么用

  • 在资源有限地区,除推动更强效抗逆转录病毒药物可及性外,仍需有效的ART依从性支持策略用于妊娠期启动治疗的女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated viral load (VL) early after antiretroviral therapy (ART) initiation appears frequently in pregnant and postpartum women living with human immunodeficiency virus; however the relative contributions of pre-ART drug resistance mutations (DRMs) vs nonadherence in the etiology of elevated VL are unknown. METHODS: Within a cohort of women initiating ART during pregnancy in Cape Town, South Africa, we compared women with elevated VL after initial suppression (cases, n = 80) incidence-density matched to women who maintained suppression over time (controls, n = 87). Groups were compared on pre-ART DRMs and detection of antiretrovirals in stored plasma. RESULTS: The prevalence of pre-ART DRMs was 10% in cases and 5% in controls (adjusted odds ratio [aOR], 1.53 [95% confidence interval {CI}, .4-5.9]); all mutations were to nonnucleoside reverse transcriptase inhibitors. At the time of elevated VL, 19% of cases had antiretrovirals detected in plasma, compared with 87% of controls who were suppressed at a matched time point (aOR, 131.43 [95% CI, 32.8-527.4]). Based on these findings, we estimate that <10% of all elevated VL in the cohort may be attributable to pre-ART DRMs vs >90% attributable to ART nonadherence. CONCLUSIONS: DRMs account for a small proportion of all elevated VL among women occurring in the 12 months after ART initiation during pregnancy in this setting, with nonadherence appearing to drive most episodes of elevated VL. Alongside the drive for access to more robust antiretroviral agents in resource-limited settings, there is an ongoing need for effective strategies to support ART adherence in this patient population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Myer L, Redd AD, Mukonda E, et al. Antiretroviral Adherence, Elevated Viral Load, and Drug Resistance Mutations in Human Immunodeficiency Virus-infected Women Initiating Treatment in Pregnancy: A Nested Case-control Study. Clin Infect Dis. 2020. PMID: 30877752. doi:10.1093/cid/ciz209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。